



Advancements and Challenges in Treating Chronic Myeloproliferative Neoplasms

Guest Editors:

Dr. Ivan Krečak

1. Department of Internal Medicine, General Hospital of Šibenik-Knin County, Šibenik, Croatia
2. Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Dr. Marko Skelin

1. Pharmacy Department, General Hospital of Šibenik-Knin County, Šibenik, Croatia
2. Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Dr. Zinaida Perić

1. Division of Hematology, University Hospital Rijeka, Rijeka, Croatia
2. Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Deadline for manuscript submissions:

25 August 2024

Message from the Guest Editors

Dear Colleagues,

This is an invitation to be part of a new Special Issue of the *Journal of Clinical Medicine (JCM)* entitled “Advancements and Challenges in Treating Chronic Myeloproliferative Neoplasms”. BCR::ABL1-negative chronic myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are disorders characterized by strong myeloproliferation, a chronic inflammatory state, the presence of various disease-related debilitating symptoms, high cardiovascular risk, and the intrinsic tendency to transform into secondary MF or acute leukemia. In recent years, significant advances in the MPN field have profoundly affected the diagnostic and therapeutic landscapes in MPNs.

Therefore, the aim of this Special Issue is to give *JCM* readers an update on the diagnosis and the contemporary management of MPNs. In addition, manuscripts covering current controversies in the MPN field as well as original research articles providing novel concepts related to the pathophysiology, risk stratification, and management of MPNs are welcomed.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, University
of Tokyo, Tokyo 113-8655, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)